贝那普利联合保肾康治疗慢性肾小球肾炎的临床疗效分析及其价值研究

摘要

目的：探讨贝那普利联合保肾康治疗慢性肾小球肾炎的临床疗效及其价值。方法：选取2013年12月-2015年12月本院收治的已明确诊断为原发性慢性肾小球肾炎180例患者作为研究对象，按照随机数字表法将其分为对照组92例和观察组88例。对照组给予盐酸贝那普利片口服治疗，观察组给予盐酸贝那普利片+保肾康联合治疗，4周为一疗程，两组均连续治疗4个疗程。观察并比较两组治疗前后血压、24 h尿蛋白定量情况及总有效率。结果：治疗前，对照组血压（139±12）/（78±7） mm Hg，观察组（138±11）/（80±9） mm Hg，比较差异无统计学意义（P>0.05）；治疗后，对照组血压（136±10）/（76±7） mm Hg，观察组（135±10）/（78±8） mm Hg，两组血压均较治疗前有所降低，但比较差异均无统计学意义（P>0.05），且两组间比较差异亦无统计学意义（P>0.05）。治疗前，对照组24 h尿蛋白定量为（1.87±0.62）g，观察组24 h尿蛋白定量为（1.92±0.67）g，比较差异无统计学意义（P>0.05）；治疗后，对照组24 h尿蛋白定量为（0.89±0.45）g，观察组24 h尿蛋白定量为（0.61±0.41）g，两组24 h尿蛋白定量均较治疗前明显降低，且治疗后观察组明显低于对照组，比较差异均有统计学意义（P<0.05）。观察组治疗总有效率为94.32%，高于对照组的78.26%，比较差异有统计学意义（P<0.05）。结论：贝那普利联合保肾康治疗慢性肾小球肾炎降低尿蛋白效果明显，可提高患者治疗有效率。%Objective:To explore the clinical efficacy and value of Benazepril combined with Piperazine Ferulate Tablets in the treatment of chronic glomerulonephritis.Method:From December 2013 to December 2015,180 cases of clearly diagnosed to suffer from primary chronic glomerulonephritis in our hospital were selected as the research objects,they were divided into the control group of 92 cases and the observation group of 88 cases according to the random number table method.The control group was given oral Benazepril Hydrochloride Tablets therapy and the observation group was given Benazepril Hydrochloride Tablets combined with Piperazine Ferulate Tablets therapy,4 weeks for 1 courses of treatment and two groups were continuous treatment of 4 courses.The blood pressure,24 h urine protein quantity before and after treatment and total effective rate of two groups were observed and compared.Result:Before treatment,the blood pressure in the control group was (139±12)/(78±7) mm Hg and that of the observation group was(138±11)/(80±9) mm Hg,the difference was not statistically significant(P>0.05).After treatment,the blood pressure in the control group was (136±10)/(76±7) mm Hg and that of the observation group was(135±10)/(78±8) mm Hg,the blood pressure in two groups was lower than before treatment,but there was no significant difference,and there was no significant difference of two groups(P>0.05).Before treatment,the urine protein quantitative within 24 h in the control group was(1.87±0.62)g,while that of the observation group was(1.92±0.67)g,the difference was not statistically significant(P>0.05).After treatment,the urine protein quantitative within 24 h in the control group was (0.89±0.45)g,while that of the observation group was(0.61±0.41)g,the urine protein quantitative within 24 h in two groups were significantly lower than that of before treatment(P<0.05),and the the urine protein quantitative within 24 h in the observation group after treatment was significantly lower thanthat of the control group(P<0.05).The total effective rate in the observation group was 94.32%,higher than 78.26% of the control group,the difference was statistically significant(P<0.05).Conclusions:Benazepril Hydrochloride Tablets combined with Piperazine Ferulate Tablets has obvious effects in the treatment of chronic glomerulonephritis for reducing the urine protein and improving the effective rate.